Short-course Radiotherapy Combined With Sintilimab for Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma
This study is aimed to evaluate the efficacy and safety of short-course radiotherapy combined with sintilimab in neoadjuvant treatment of stage III, locally advanced esophageal squamous cell carcinoma.
Esophageal Squamous Cell Carcinoma
DRUG: sintilimabï¼Œprogrammed death 1 monoclonal antibody
Pathological complete response, Total tumor regression rate under pathologyPrimary tumor or lymph node surgery specimen pathological examination without residual tumor cell, 4 weeks after surgery|Incidence rate of adverse events, The ratio of the number of cases with adverse events to the total number of cases available for evaluation., 3 years
overall survival, the time from randomization to death, 3 years|Disease-free survival, the time from treatment until the recurrence of disease (or death) after undergoing curative-intent treatment, 3 years
This study was designed as a single arm, phase II trial. Subjects will receive short-course radiotherapy combined with sintilimab as neoadjuvant therapy of stage III, locally advanced esophageal squamous cell carcinoma. The primary endpoint is pathologic complete response(pCR).